

## **PolyPid Announces Presentation at the American College of Surgeons Clinical Congress 2023**

PETACH TIKVA, Israel, Oct. 09, 2023 — PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that SHIELD I Phase 3 clinical data for D-PLEX<sub>100</sub> will be highlighted in a presentation at the American College of Surgeons Clinical Congress 2023, to be held on October 22-25, 2023, in Boston, MA.

### **American College of Surgeons Clinical Congress 2023**

Presentation Impact of Locally Applied Doxycycline-Eluting Drug (D-PLEX) on Incisional  
Title: Infection Rate in Elective Colorectal Surgery: A Phase 3, Prospective, Randomized, Double-Blind, Multicenter, and Multinational Clinical Trial

Presenter: Shmuel Sharoni, M.D.

Date/Time: October 23, 2023/4:15 PM – 5:45 PM Eastern Time

Location: Session SF120 – Colon and Rectal Surgery I  
BCEC Ballroom East, Level 3

The abstract will be available on [www.polypid.com](http://www.polypid.com) once the conference concludes.

### **About PolyPid**

PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matrix) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX<sub>100</sub> is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma.

For additional Company information, please visit <http://www.polypid.com> and follow us on Twitter and LinkedIn.

### **Contacts:**

PolyPid Ltd.

Ori Warshavsky

COO – US

908-858-5995

IR@Polypid.com

### **Investors:**

Brian Ritchie  
LifeSci Advisors  
212-915-2578  
britchie@lifesciadvisors.com

